首页 产品中心
  • Verdinexor (KPT-335)

    • ATG-527
    货号: abs817730
    CAS号: 1392136-43-4
    分子式: C18H12F6N6O
    分子量: 442.32
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs817730-2mg 1-2周 ¥1294.00
    - +
    abs817730-5mg 1-2周 ¥1940.00
    - +
    abs817730-10mg 1-2周 ¥3457.00
    - +
    abs817730-25mg 1-2周 ¥7919.00
    - +
    大包装询价
    产品描述
    描述
    Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.
    纯度
    98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    ATG-527
    可溶性/溶解性
    DMSO :88 mg/mL (198.95 mM)
    生物活性
    靶点
    CRM1
    In vitro(体外研究)
    Verdinexor inhibits the viability of Jurkat, OCI-Ly3, OCI-Ly10, and CLBL1 cells with IC50 of 0.3 nM, 2.1 nM, 41.8 nM, and 8.5 nM, respectively. KPT-335 also induces apoptosis in CLBL1 cells and primary canine DLBCL cells that express XPO1 and SINE. Verdinexor potently and selectively inhibits vRNP export and effectively inhibits the replication of various influenza virus A and B strains, including pandemic H1N1 virus, highly pathogenic H5N1 avian influenza virus, and the recently emerged H7N9 strain.
    In vivo(体内研究)
    Verdinexor (25 mg/kg twice daily, p.o.) reduces proinflammatory cytokine expression in the lung, produces in vivo antiviral activity by reducing lung virus titers, and thus reduces pulmonary disease pathogenesis and death associated with lethal influenza A virus challenge. In autosomal-dominant polycystic kidney disease model, Verdinexor (5 mg/kg, i.p.) attenuates cyst growth via inhibition of XPO1.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0 张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要咨询”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要咨询

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0